Ponatinib companion diagnostic - ARIAD Pharmaceuticals/MolecularMD

Drug Profile

Ponatinib companion diagnostic - ARIAD Pharmaceuticals/MolecularMD

Latest Information Update: 17 Feb 2017

Price : $50

At a glance

  • Originator ARIAD Pharmaceuticals
  • Developer MolecularMD
  • Class Diagnostic agents
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Acute lymphoblastic leukaemia; Chronic myeloid leukaemia

Most Recent Events

  • 16 Feb 2017 ARIAD Pharmaceuticals has been acquired by Takeda
  • 25 Sep 2013 Discontinued - Preregistration for Acute lymphoblastic leukaemia in USA (unspecified route)
  • 25 Sep 2013 Discontinued - Preregistration for Chronic myeloid leukaemia in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top